


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**In the Claims:**

1. (Currently Amended) A compound of the Formula (I):



(I)

or a salt, solvate, or physiologically functional derivative thereof wherein:


~~A is aryl optionally substituted with at least one R<sup>1</sup> group, heteroaryl, C<sub>4</sub>-C<sub>6</sub> alkenyl, C<sub>4</sub>-C<sub>6</sub> alkynyl, CN, halo, COOH, C(O)NR<sup>4</sup>R<sup>5</sup>, -NRR', N(R')S(O)<sub>2</sub>R, N(R')C(O)R, or N(R')C(O)NR<sup>4</sup>R<sup>5</sup>;~~

~~R<sup>1</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl, aryl, C<sub>1</sub>-C<sub>6</sub> alkoxy, aryloxy, halo, -COOH, -CN, -S(O)<sub>2</sub>NR<sup>4</sup>R<sup>5</sup>, -S(O)<sub>2</sub>R, -C(O)NR<sup>4</sup>R<sup>5</sup>, -NRR', -N(H)C(O)NR<sup>4</sup>R<sup>5</sup>, -O(CH<sub>2</sub>)<sub>n</sub>COOH, -(CH<sub>2</sub>)<sub>n</sub>COOH, -C(O)O(CH<sub>2</sub>)<sub>n</sub>R, -(CH<sub>2</sub>)<sub>n</sub>N(H)C(O)OR, or -N(R')S(O)<sub>2</sub>R;~~

R is -H, C<sub>1</sub>-C<sub>6</sub> alkyl, aryl, or heteroaryl;

R' is -H or C<sub>1</sub>-C<sub>3</sub> alkyl;

D is selected from the group consisting of:



$R^2$  is  $-H$ , halo,  $C_1-C_6$  alkyl,  $C_1-C_6$  alkoxy, aryl, heteroaryl,  $-S(O)_2NR^4R^5$ ,  $-COOH$ ,  $-C(O)OR^6$ ,  $-C(O)NR^4R^5$ ,  $NRR'$ ,  $-N(H)C(O)NRR'$ ,  $-N(H)C(O)R$ , or  $-N(H)S(O)_2R$ ;  
 $q$  is 1, 2, 3, or 4;

$R^3$  is  $-H$ ,  $C_1-C_3$  alkyl, aryl, aralkyl, or heteroaryl;

$R^4$  is  $-H$  or  $C_1-C_3$  alkyl;

$R^5$  is  $-H$  or  $C_1-C_3$  alkyl; or

$R^4$  and  $R^5$  together with the nitrogen to which they are attached form a heterocyclyl ring, said ring optionally containing 1 or 2 additional oxygen,  $S(O)_m$ , or nitrogen atoms; said nitrogen atoms being optionally substituted by a  $C_1-C_3$  alkyl group;

$m$  is 0, 1, or 2; and


$R^6$  is  $C_1-C_6$  alkyl.

2 – 6. (Cancelled)

7. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and one or more of pharmaceutically acceptable carriers, diluents and excipients.

8. (Cancelled)

9. (Currently Amended) The compound of claim 1 8, wherein D is:



10 – 13. (Cancelled)

14. (Currently Amended) A The compound of claim 1, wherein said compound is selected from the group consisting of:

~~3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine;~~

~~5-bromo-3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine;~~

~~3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-phenylpyrazin-2-amine;~~

~~3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-(3,4,5-trimethoxyphenyl)pyrazin-2-amine;~~

~~3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-(4-fluorophenyl)pyrazin-2-amine;~~

~~3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-thien-2-ylpyrazin-2-amine;~~

~~5-(4-aminophenyl)-3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine;~~

~~3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-pyridin-3-ylpyrazin-2-amine;~~

~~3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1H-indol-5-yl)pyrazin-2-amine;~~

~~3-[1-(2-methoxyethyl)-1H-benzimidazol-2-yl]-5-thien-2-ylpyrazin-2-amine;~~

~~3-(1H-benzimidazol-2-yl)-5-(3-fluorophenyl)pyrazin-2-amine;~~

~~3-(1H-benzimidazol-2-yl)-5-(4-fluorophenyl)pyrazin-2-amine;~~

~~4-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]-N,N-dimethylbenzenesulfonamide;~~

~~3-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)-5-[3-(methylsulfonyl)phenyl]pyrazin-2-amine;~~

3-{4-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]phenyl}propanoic acid;

{4-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]phenoxy}acetic acid;

{3-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]phenoxy}acetic acid;

N-{4-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]phenyl}methanesulfonamide;

benzyl 4-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]benzoate;

5-[4-(benzyloxy)phenyl]-3-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine;

5-[1,1'-biphenyl-3-yl]-3-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine;

4-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]benzoic acid;

tert-butyl 3-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]  
~~benzylcabamate~~benzylcarbamate;

~~3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1H-pyrrol-2-yl)pyrazin-2-amine;~~

~~3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1H-indol-2-yl)pyrazin-2-amine; and~~

~~5-[(4-aminophenyl)ethynyl]-3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine;~~

or a salt, solvate, or physiologically functional derivative thereof.

15. (Cancelled)